Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 induction study of duvakitug in moderately to severely active ulcerative colitis
jRCT2031250558Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of duvakitug in autoimmune colitis (3 arms), sponsored by Sanofi. Primary endpoint: Clinical remission at Week 12. Started Dec 2025; status: recruiting.
02
Drugs
duvakitug
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2031250558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250558.